A 2-month course of therapy to prevent active tuberculosis in patients infected with the human immunodeficiency virus (HIV) is an effective alternative to the 12-month regimen currently recommended for people coinfected with HIV and tuberculosis (TB), according to a study of nearly 1600 patients in 4 countries. More than 5 million people worldwide are infected with both HIV and Mycobacterium tuberculosis and are at high risk of developing active TB.
The multinational effort was sponsored by the National Institute of Allergy and Infectious Diseases, the Pan American Health Organization, and the Centers for Disease Control and Prevention. Preliminary results of the study were presented last month at the Fifth Conference on Retroviruses and Opportunistic Infections in Chicago, Ill.
Stephenson J. TB Prophylaxis and HIV. JAMA. 1998;279(11):818. doi:10.1001/jama.279.11.818-JHA80001-2-1
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: